Endocrine Abstracts

Polycystic ovary syndrome (PCOS) is a hormonal imbalance caused by ovarian dysfunction representing one of the most common endocrine metabolic disorder in reproductive aged women. PCOS is highly correlated with resistance to insulin and abnormal increase of androgen levels. Myo-inositol (MI) supplementation in women with PCOS has been evaluated over the last years. Many hormonal and reproductive dysfunctions associated with this disorder have been proven to be relieved by the supplement. Specifically, it was noted to increase the insulin sensitivity, reduce androgen levels and normalize the menstrual cycle. The meta-analysis was done using the systematic search performed in MEDLINE, EMBASE, PubMed and Research Gate from the inception until October 20th, 2021. Randomized controlled trials (RCTs) included women with PCOS and groups having inositols, metformin and placebo. The primary outcome was the beneficial effect of the drug on menstrual cycle whereas secondary outcomes were body mass index (BMI), parameters of carbohydrate metabolism, clinical and laboratory hyperandrogenism. Results are reported as risk ratios or mean differences (MDs) with 95% confidence intervals (CIs). In women with PCOS, treatment with metformin (MET) ameliorated the insulin sensitivity and decreased the androgens levels, but the limitations to MET use are its gastrointestinal side effects. In this case of PCOS, the role of myo-inositol was evaluated. Polycystic ovary syndrome is a complex polygenic and multifactorial disorder. Pathophysiological abnormalities in gonadotropin secretion, disruptions of ovarian folliculogenesis, impaired steroidogenesis, impaired insulin action and secretion are prominent symptoms of this condition. Studies show that MI leads to a decrease in LH and androgen levels, as well as a decrease in insulin resistance. Thus, MI is believed to be able to re-establish ovulatory menstrual cycles (especially in obese women with PCOS). Insulin resistance, elevated androgen levels disturb normal menstrual cycle and lead to anovulation further causing infertility. Myo-inositol (MI) improves the menstrual cycle, insulin sensitivity and other symptoms leading to successful pregnancies.